RxDoctor Payments Data

Raymond Morris, MD

Psychiatry · Middletown, CTNPI 1184988867

Payments from drug & device makers

$759in general payments, 2019–2025

Across 41 payments — averaging $18.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$272
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$199
  • Takeda Pharmaceuticals U.S.A., Inc.$87
  • E.r. Squibb & Sons, L.L.C.$73
  • Otsuka America Pharmaceutical, Inc.$30
  • Indivior Inc.$23
  • plus $76 from 4 others

What the payments were for

  • Food & beverage$68490%
  • Education$7410%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$759 in reported general payments places this provider in the 70th percentile of 644 psychiatry providers in Connecticut.

See all psychiatry providers in Connecticut

Medicare billing

Part B allowed, 2024
$34,544
Medicare patients
58
Services billed
324

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl155$208,902
Invega SustennaPaliperidone Palmitate64$200,719
IngrezzaValbenazine Tosylate12$115,632
Abilify MaintenaAripiprazole23$69,133
AustedoDeutetrabenazine17$54,690
BelsomraSuvorexant128$42,980
AristadaAripiprazole Lauroxil12$41,140
PerserisRisperidone12$28,728
CaplytaLumateperone Tosylate14$25,673
Lurasidone Hcl107$24,301
Risperidone ErRisperidone Microspheres21$20,668
TrintellixVortioxetine Hydrobromide38$19,481
Clozapine359$18,585
Olanzapine449$16,974
QuviviqDaridorexant Hcl34$16,781

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$272$208,902155 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$30$69,13323 claims
Alkermes, Inc.Aristada$19$41,14012 claims
Indivior Inc.Perseris$23$28,72812 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$199$25,67314 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$87$19,48138 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 644 psychiatry providers in Connecticut.

Other psychiatry in Middletown

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →